No quarterly revenue total was found in PASSAGE BIO, INC.'s SEC filings.
Passage Bio, Inc. (PASG) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income
$-7.82M
+16.7% vs year-ago quarter
Operating cash flow
$-9.18M
-45.0% vs year-ago quarter
Free cash flow
—
EPS
$-2.44
+17.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
3.22M
+1.2% vs year-ago quarter
Net cash
$27.58M
Q1 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PASG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Philadelphia, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1787297
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$8.3M | -$8.2M | -$13.8M | -$8.7M | -$10.3M |
| Net income | -$7.8M | -$7.6M | -$13.0M | -$7.7M | -$9.4M |
| Diluted EPS | -$2.44 | -$2.36 | -$4.08 | -$2.44 | -$2.96 |
| Operating cash flow | -$9.2M | -$13.0M | -$6.5M | -$4.9M | -$6.3M |
| Total assets | $25.2M | $36.5M | $62.3M | $74.2M | $79.2M |
| Total liabilities | $20.7M | $24.7M | $43.5M | $43.0M | $40.9M |
| Stockholders' equity | $4.5M | $11.8M | $18.8M | $31.1M | $38.3M |
| Cash and investments | $24.2M | $33.3M | $46.3M | $52.8M | $57.6M |
| Total debt | — | $5.8M | $24.0M | $24.3M | $24.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 3, 2026 | Sep 2, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure, Other events
|
Jun 24, 2026 | Jun 23, 2026 |
| 8-K |
Current report
Agreement ended
|
May 27, 2026 | May 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 26, 2026 | May 19, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 442 Passage Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.